Synbiotics

Synbiotics is pioneering a new era in oncolytic virus therapies with enhanced targeting, improved safety, and superior tumor-killing capabilities. Specializing in the research and development of oncolytic virus drugs, the company utilizes synthetic biology technology and an adenovirus platform to create highly targeted, safer, and more effective tumor-killing solutions for various cancer indications. This new generation of oncolytic virus products boasts enhanced capabilities. Founded by Professor Xie Zhen's team from the Department of Automation at Tsinghua University, Synbiotics operates in the Biotechnology, Health Care, and Pharmaceutical industries. As of now, specific information about the company's funding, investors, founding date, and headquarters location is not available. However, Synbiotics' innovative approach to oncolytic virus therapies and its use of advanced technology make it a noteworthy candidate for potential venture capital investment.